Viking Therapeutics, Inc.
GB ˙ LSE ˙ US92686J1060
29,87 $ ↑0,55 (1,88%)
2026-06-04
DEL PRIS
SecurityGB:0VQA / Viking Therapeutics, Inc.
InstitutionCornerstone Capital, Inc.
Latest Disclosed Ownership86,900 shares
Latest Disclosed Value $ 2,827,726
Cornerstone Capital, Inc. reports 285.37% increase in ownership of 0VQA / Viking Therapeutics, Inc.

On May 12, 2026 - Cornerstone Capital, Inc. filed a 13F-HR form disclosing ownership of 86,900 shares of Viking Therapeutics, Inc. (GB:0VQA) valued at $2,832,940 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 22,550 shares of Viking Therapeutics, Inc.. This represents a change in shares of 285.37% during the quarter. The current value of the position is $2,595,703 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 86,900 64,350 285.37 2,828 256.49 0.2824
2026-02-12 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 22,550 0 0.00 793 33.95 0.0782
2025-11-10 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 22,550 -1,730 -7.13 593 -7.93 0.0580
2025-08-12 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 24,280 0 0.00 643 9.73 0.0673
2025-05-13 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 24,280 -520 -2.10 586 -41.22 0.0631
2025-02-13 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 24,800 -4,970 -16.69 998 -47.08 0.1051
2024-10-30 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 29,770 -4,180 -12.31 1,885 4.72 0.1760
2024-08-02 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 33,950 0 0.00 1,800 -35.36 0.1815
2024-05-01 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 33,950 -76,025 -69.13 2,784 36.02 0.2855
2024-02-02 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 109,975 -170 -0.15 2,047 67.84 0.2242
2023-11-13 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 110,145 0 0.00 1,219 -31.71 0.1469
2023-08-21 2023-06-30 13F VIKING THERAPEUTICS COM 92686J106 110,145 -44,510 -28.78 1,785 -30.68 0.2065
2023-05-15 2023-03-31 13F VIKING THERAPEUTICS COM 92686J106 154,655 15,300 10.98 2,575 96.72 0.3108
2023-02-13 2022-12-31 13F VIKING THERAPEUTICS COM 92686J106 139,355 -4,625 -3.21 1,310 233.93 0.1678
2022-10-27 2022-09-30 13F VIKING THERAPEUTICS COM 92686J106 143,980 4,840 3.48 392 -2.49 0.0551
2022-08-15 2022-06-30 13F VIKING THERAPEUTICS COM 92686J106 139,140 4,095 3.03 402 -0.74 0.0515
2022-05-13 2022-03-31 13F VIKING THERAPEUTICS COM 92686J106 135,045 12,825 10.49 405 -27.94 0.0454
2022-02-11 2021-12-31 13F VIKING THERAPEUTICS COM 92686J106 122,220 0 0.00 562 -26.82 0.0599
2021-11-09 2021-09-30 13F VIKING THERAPEUTICS COM 92686J106 122,220 -12,400 -9.21 768 -4.71 0.0885
2021-08-13 2021-06-30 13F VIKING THERAPEUTICS COM 92686J106 134,620 975 0.73 806 -4.62 0.0914
2021-05-17 2021-03-31 13F VIKING THERAPEUTICS COM 92686J106 133,645 5,180 4.03 845 16.87 0.1022
2021-02-12 2020-12-31 13F VIKING THERAPEUTICS COM 92686J106 128,465 3,000 2.39 723 -0.96 0.0930
2020-10-27 2020-09-30 13F VIKING THERAPEUTICS COM 92686J106 125,465 10,852 9.47 730 -11.62 0.1052
2020-08-14 2020-06-30 13F VIKING THERAPEUTICS COM 92686J106 114,613 2,838 2.54 826 57.93 0.1407
2020-05-15 2020-03-31 13F VIKING THERAPEUTICS COM 92686J106 111,775 -134,021 -54.53 523 -73.47 0.1087
2020-02-10 2019-12-31 13F VIKING THERAPEUTICS COM 92686J106 245,796 -2,329 -0.94 1,971 15.47 0.2780
2019-11-13 2019-09-30 13F VIKING THERAPEUTICS COM 92686J106 248,125 -1,000 -0.40 1,707 -17.46 0.2656
2019-08-14 2019-06-30 13F VIKING THERAPEUTICS COM 92686J106 249,125 4,325 1.77 2,068 -15.00 0.3244
2019-05-15 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 244,800 32,200 15.15 2,433 49.63 0.4023
2019-02-11 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 212,600 32,479 18.03 1,626 -48.18 0.2899
2018-11-13 2018-09-30 13F VIKING THERAPEUTICS COM 92686J106 180,121 34,621 23.79 3,138 127.23 0.4770
2018-08-13 2018-06-30 13F VIKING THERAPEUTICS COM 92686J106 145,500 58,850 67.92 1,381 264.38 0.2346
2018-05-08 2018-03-31 13F VIKING THERAPEUTICS COM 92686J106 86,650 0 0.00 379 7.67 0.0624
2018-02-12 2017-12-31 13F VIKING THERAPEUTICS COM 92686J106 86,650 86,650 352 0.0597
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.